Our history of innovation began shortly after our company’s inception, with the launch of the Ventana ES in 1991. The ES was the world’s first barcode-driven instrument, that automated immunohistochemistry (IHC) and provided standardization and speed to tests that were traditionally performed by hand. This gain in speed and accuracy dramatically reduced the time patients waited to receive their results.
In 1997, our INFORM HER-2/neu FISH (fluorescence in situ hybridization) DNA probe assay became the first diagnostic test approved by the FDA for the evaluation of HER2 status in breast cancer. This test serves as an indicator of response, or lack of response, to many standard treatments for breast cancer allowing physicians to more closely personalize isolated treatment of breast cancer patients.
Innovation gained further momentum in 2000 by introducing the BenchMark system, the world’s first fully automated system for IHC and in situ hybridization (ISH). Since then, Ventana has been instrumental in launching more advanced family of BenchMark systems to include the latest, BenchMark ULTRA. This instrument performs simultaneous IHC and ISH testing on a single, continuous, and random-access platform (samples can be added and removed at any time without interrupting workflow).
In 2006, the Ventana SYMPHONY system was launched. This fully automated platform transformed hematoxylin and eosin (H&E) staining by combining the entire process of baking, de-waxing, staining, and coverslipping to determine the patient’s first and most critical diagnosis of cancer. The SYMPHONY delivers high-quality tissue staining results that pathologist use to improve productivity and workflow in histology laboratories.
In 2007, PATHWAY HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody received approval from the US Food and Drug Administration (FDA) as an aid in assessing breast cancer patients for whom Herceptin® treatment is considered. This test provides pathologists and oncologists with a high medical value diagnostic tool and serves as an additional example of our continued innovation and investment in cancer treatment and personalized healthcare.
Automated standardization and tissue diagnostics may have been the primary driving force in the early stages of Ventana but over the last decade, we have broadened our focus to cover every step involved in the analysis of patient tissue samples.
The Ventana workflow management system, VANTAGE, enables labs to track samples and manage workflow from the beginning to the end in real-time for improved patient safety, productivity and quality. Ventana understands that not only does the quality of tissue staining and automation drive timely and accurate diagnosis for patients, but the value of positive patient identification tracking is vital to deliver the right diagnosis, to the right patient.